10-Q · May 7, 2026
Intensity Therapeutics reported no revenue for the quarter ending March 31, 2026, continuing a trend of zero revenue since inception. The company incurred a loss of $2.434 million compared to a loss of $3.347 million in…
Earnings analysis · 10-Q
INTS earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Intensity Therapeutics remains a pre-revenue clinical biotechnology company with no reported product or licensing revenue and a Q2 2026 net loss of $3.007 million, worse than the $2.537 million loss in Q2 2025.…
Read full summary
Intensity Therapeutics remains a pre-revenue clinical biotechnology company with no reported product or licensing revenue and a Q2 2026 net loss of $3.007 million, worse than the $2.537 million loss in Q2 2025. Six-month losses and operating cash burn improved year over year, while INVINCIBLE-4 treatment resumed and INVINCIBLE-3 enrollment activities restarted. However, the company reported $9.5 million of cash, $4.166 million of six-month operating cash use, and substantial doubt about its ability to continue as a going concern, making additional financing the principal near-term risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Six-Month Loss Improved
Six-month net loss improved to $5.441 million from $5.884 million in the prior-year period, a $0.443 million improvement. The quarterly net loss was $3.007 million versus $2.537 million in Q2 2025, a $0.470 million deterioration.
-
Operating Costs Declined Year Over Year
Six-month operating expenses declined to $5.610 million from $6.099 million, primarily because research and development expense fell $0.702 million, or 19%, to $3.028 million.
-
INVINCIBLE-4 Treatment Restarted
INVINCIBLE-4 enrollment resumed in Q2 2026 after a protocol amendment, and the company restarted patient treatment in July 2026. Preliminary data from 14 patients showed a 71% pCR rate in the INT230-6 cohort versus 42% for standard of care.
-
INVINCIBLE-3 Restart Planned
The company initiated activities to resume INVINCIBLE-3 enrollment at a limited number of U.S. sites, with patient enrollment likely to begin in Q3 2026. The trial had enrolled 21 patients before the March 2025 funding-related pause.
-
Operating Cash Burn Moderated
Cash used in operating activities improved to $4.166 million in the first six months of 2026 from $4.445 million in the prior-year period. Financing activities provided $1.774 million, primarily from common-stock sales under the Sales Agreement.
-
Additional Equity Funding Obtained
Subsequent to June 30, 2026, the company raised $1.3 million in net proceeds through its Sales Agreement, increasing liquidity after reporting $9.5 million of cash and cash equivalents at quarter-end.
What to watch
-
Going-Concern and Funding Risk
Management stated that the financial statements include substantial doubt about the company's ability to continue as a going concern. Cash and cash equivalents were approximately $9.5 million at June 30, 2026, while six-month operating cash use was $4.166 million.
-
No Revenue and Continuing Losses
The company has not generated revenue from product sales or licensing and reported a quarterly net loss of $3.007 million. Management expects significant expenses and operating losses for the next several years while advancing clinical programs.
-
Clinical Progress Depends on Funding
INVINCIBLE-3 enrollment was paused in March 2025 because of funding constraints after 21 patients had enrolled. Although a limited restart is planned for Q3 2026, broader site activation and enrollment depend on obtaining sufficient incremental funding.
-
Risk Factors Unchanged; Deficit Expanded
The filing states that risk factors have not changed materially from the 2025 Annual Report, so no material risk-factor additions or deletions were disclosed. Nonetheless, the company reported an accumulated deficit of $83.8 million at June 30, 2026.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that it expects significant expenses and operating losses for the foreseeable future and will need additional capital to fund operations.
Earlier filings 4
10-K · March 27, 2026
Intensity Therapeutics reported no revenue for 2025, with an EPS loss of $11.606 million compared to a loss of $16.3 million in 2024, indicating a shift towards reduced losses. Management emphasizes the need for…
10-Q · November 6, 2025
Intensity Therapeutics, Inc. reported zero revenue for Q3 2025 alongside an EPS of -0.06, which matched consensus estimates. Significant operating losses of $2.67 million were attributed to ongoing research and…
10-Q · August 7, 2025
Intensity Therapeutics, Inc. reported Q2 2025 results with a net loss of $2.54 million and an improvement in EPS to -$0.13, surpassing the estimated -$0.18. No revenue was reported for the quarter, consistent with the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.